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SUMMARY
Background
Adalimumab is an effective treatment in patients with Crohn’s disease;
as it is a humanized anti-tumour necrosis factor monoclonal antibody,
immunogenicity is thought not to be of any significance.
Aim
To assess whether antibodies to adalimumab (ATAs) affect adalimumab
treatment outcome in patients with Crohn’s disease previously treated
with infliximab.
Methods
A retrospective study was performed. Patients with active Crohn’s dis-
ease and who had lost response or were intolerant to infliximab were
treated with adalimumab. Clinical response and side effects were
assessed as were serum ATAs and antibodies to infliximab (ATIs).
Results
In total 30 patients [M ⁄F (7 ⁄23)], median age 36 years (range 21–73)
were treated with adalimumab for 318 days (median range 83–632).
Clinical response was 77% (23 ⁄30), a dose escalation was necessary in
eight (27%) patients and side effects were observed in 47% (14 ⁄30). In
five patients (17%) ATAs were detected; of these patients, four were
nonresponders. The presence of ATAs was related to nonresponse to
adalimumab (P = 0.006). ATIs were positive in 57% of patients (17 ⁄30)
and serum levels were significantly increased in adalimumab non-
responders (P = 0.01).
Conclusion
Immunogenicity plays a role in adalimumab treatment because of the
development of ATAs.
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INTRODUCTION
The chimeric monoclonal antibody to tumour necrosis
factor (TNF-alpha), infliximab, is effective as an
induction and maintenance therapy for patients with
moderate-to-severe Crohn’s disease1–3 including fistula
closure4, 5 and probably even better in combination
with antibiotics.6 However, its use is associated with
the formation of antibodies to infliximab (ATIs), which
can lead to infusion reactions, loss of efficacy and
delayed hypersensitivity reactions.7–9
In contrast to infliximab, adalimumab is a fully
humanized IgG1 class anti-TNF antibody that can be
administered subcutaneously. Studies have shown that
adalimumab is effective in inducing and maintaining
clinical remission in patients with moderate-to-severe
Crohn’s disease naive to anti-TNF therapy and also in
patients previously treated with infliximab.10–12 In
addition, adalimumab is also an effective induction
therapy in patients who have previously responded
to infliximab and then lost response or become
intolerant.13
As seen in infliximab treatment, the immunogenicity
of a biological has important consequences for treat-
ment outcome and therapeutic approach, for example,
the use of concomitant immunosuppressive therapy.
The role of immunogenicity in adalimumab treatment
has not yet been fully elucidated in Crohn‘s disease.
Based on the fully humanized molecular structure of
this antibody, adalimumab would presumably be less
immunogenic than the chimeric antibody infliximab.
However, in rheumatoid arthritis patients, antibodies
to adalimumab (ATAs) were associated with lower
serum adalimumab concentrations and a nonresponse
to adalimumab therapy.14
As the role of immunogenicity in adalimumab
treatment is not clear in patients with Crohn’s disease,
this study aimed to assess whether ATAs affect
adalimumab treatment outcome in these patients.
MATERIALS AND METHODS
A retrospective study was performed and all patients
signed an informed consent for taking extra serum
samples. The first patients treated with adalimumab in
our centres were included in this study. These patients
had active luminal or fistulizing Crohn’s disease and
had lost response to or were intolerant to infliximab.
No primary nonresponders were included in this study.
The following subcutaneous regimen was used: 160 mg
at week 0, 80 mg at week 2 and 40 mg every 2 weeks.
Clinical response and side effects were assessed. Clini-
cal response for luminal disease was assessed by a
physician specialized in treating patients with Crohn’s
disease. Nonresponse was defined as no improvement
in the following clinical symptoms: general wellbeing,
abdominal pain, number of liquid or very soft stools,
presence of abdominal mass and extra-intestinal mani-
festations. For fistulizing Crohn’s disease, clinical
response was defined as a reduction of 50% or more
from baseline in the number of draining fistulas.
Closure of a perianal fistula was defined as no drain-
age despite firm finger compression. The physician
assessing clinical response was blinded to the presence
of ATAs.
Serum was taken from patients prior to adalimumab
treatment for the detection of ATIs and during treat-
ment for the detection of ATAs. Serum ATAs levels
were only measured when the minimum adalimumab
treatment duration was 60 days. Serum ATAs and ATIs
levels were detected with a radioimmunoassay as
described by Bartelds et al.14 and Wolbink et al.15 The
cut-off level for a positive signal was set at 12 AU ⁄mL
for both assays.
Data were analysed as frequencies and percentages.
Differences between responders and nonresponders
were assessed using the chi-squared test. The Fisher’s
exact test was used to assess the relationship between
clinical response and the presence of ATAs and ATIs.
The antibodies levels are presented as means 
standard error of mean, unless stated otherwise. The
differences in the mean serum ATIs levels between
responders and nonresponders were assessed using the
Student’s t-test. Two-sided P-values <0.05 were con-
sidered to indicate statistically significant differences.
All analyses were performed using SPSS 14.0 for
Windows (SPSS Inc., Chicago, IL, USA).
RESULTS
In total, 30 patients previously treated with infliximab
were included in this study. Patient characteristics are
described in Table 1. Median adalimumab treatment
duration was 318 days (range 83–632). Overall clinical
response was 77% (23 ⁄30); 81% (18 ⁄22) in patients
with luminal and 63% (five of eight) in patients with
fistulizing disease. A dose escalation to 40 mg weekly
was necessary in eight patients (27%) of which six
patients finally responded. Side effects were observed
in 47% (14 ⁄30) of patients leading to withdrawal of
IMMUNOGENIC ITY IN ADAL IMUMAB TREATMENT FOR CROHN’S DISEASE 1123
ª 2008 The Authors, Aliment Pharmacol Ther 28, 1122–1126
Journal compilation ª 2008 Blackwell Publishing Ltd
treatment in six. The main side effects were headache,
fever and rash, but no severe side effects occurred.
The median time between initial adalimumab treat-
ment and the assessment of ATAs was 346 days (range
68–671). ATAs were detected in five patients (17%); of
these patients, four were nonresponders. The presence
of ATAs was related to a nonresponse to adalimumab
(OR 13.1, 95% CI: 1.7–99.2, P = 0.006; Figure 1).
When patients with luminal and fistulizing disease
were assessed separately, no relationship between the
presence of ATAs and clinical response was found in
the patients with fistulizing disease. However, for
patients with luminal disease, ATAs were detected in
75% (three of four) of the nonresponders compared to
5.6% (one of 17) of the responders. In this subgroup,
the presence of ATAs was associated with nonresponse
(OR 13.5, 95% CI: 1.9–98.5, P = 0.01).
Of the 13 patients using concomitant medication,
only one was found to have ATAs (7.7%) while of the
17 patients without immune suppression, four patients
developed ATAs (20%). This difference was not signifi-
cant. Furthermore, of the eight patients requiring a
dose escalation, only two were found to have ATAs.
There was no relationship between the presence of
ATAs and the requirement for dose escalation.
Antibodies to infliximab were found in 57% (17 ⁄30)
of patients; the mean serum ATIs level was
246.3  75.3 AE ⁄mL. Of the 17 ATIs positive patients,
12 were responders and five nonresponders to ada-
limumab. No relationship was found between the pres-
ence of ATIs and response to adalimumab therapy.
However, serum ATIs levels were significantly
increased in adalimumab nonresponders (responders
vs. nonresponders: 163.0  58.6 vs. 520.4  244.0
AE ⁄mL, P = 0.01). No relationship was observed
between the presence of ATAs and ATIs.
DISCUSSION
Adalimumab is an effective treatment in patients with
Crohn’s disease and as it is a humanized anti-TNF
monoclonal antibody, immunogenicity is thought not
to be of any significance. However, in this study,
patients were found to develop ATAs, which nega-
tively influenced response to adalimumab treatment.
To our knowledge, this is the first study in patients
with Crohn’s disease to find that immunogenicity
affects the outcome of adalimumab treatment. Previ-
ous studies did not find a correlation between the
presence of ATAs and loss of response to adalimumab.
The adalimumab induction and continuation trial for
maintenance of remission10, 11 only included inflix-
imab naı¨ve patients. In both studies, a small number
of patients developed antibodies, 0.04% (one of 225)
and 2.6% (seven of 269) respectively and no relation-
ship was found between clinical response and the
presence of ATAs. The difference in occurrence of
antibody formation between these trials and our study
might be explained by the difference in inclusion cri-
teria; infliximab naı¨ve patients versus those previously
Table 1. Patient characteristics
Patients
(n = 30)
Gender (M ⁄ F) 7 ⁄ 23
Age (years), median (range) 36 (21–73)
Type of Crohn’s disease
Luminal 22
Fistulizing 8
Reason for infliximab discontinuation
Loss of response 4
Intolerance 23
Unknown 3
Concomitant medication 13
Corticosteroids 4
Any immunosuppressive agent
Azathioprine 4
Mercaptopurine 1
Methotrexate 4
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Figure 1. The relationship between the presence of
antibodies to adalimumab (ATAs) and response to
adalimumab treatment. The presence of ATAs was related
to a nonresponse to adalimumab (OR 13.1, CI: 1.7–99.2,
P = 0.006).
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treated with infliximab. Previous infliximab treatment
might be an important immunizing factor increasing
the rate of adalimumab immunogenicity. In the Gaug-
ing Adalimumab Efficacy in Infliximab Nonresponders
(GAIN) study, patients with infliximab refractory dis-
ease were included, as in our study13 but none of these
patients developed ATAs. However, follow-up was
only 4 weeks in the GAIN study.
In the initial studies evaluating the efficacy and
safety of adalimumab in patients with rheumatoid
arthritis, ATAs were found in patients, but no correla-
tion with clinical response was seen.16 However, in a
more recent study in patients with rheumatoid arthri-
tis, findings similar to those in this study14 were
reported. In a prospective study, Bartelds et al. evalu-
ated adalimumab and adalimumab antibody levels in
relation to clinical response in a cohort of 121 rheu-
matoid arthritis patients up to 28 weeks after initiation
of adalimumab treatment. Similar to our results, 17%
of the patients tested positive for ATAs, this was also
associated with lower serum adalimumab concentra-
tions and nonresponse to adalimumab therapy.
There are two possible explanations for the discrep-
ancy in the incidence and effect of ATAs in the studies
mentioned above. First, in some studies, the follow-up
time might have been too short to identify all patients
with antibodies and to detect an effect on treatment
outcome. Secondly, these differences could be because
of the use of different assays, as Bartelds et al.14 dis-
cussed in their study. Therefore, assays must be stan-
dardized to compare studies and to gain more insight
into the effect of antibody formation on therapeutic
outcome in patients treated with adalimumab.
In infliximab treatment, immunomodulators are
often used as they are thought to suppress the forma-
tion of ATIs.7, 8 The question arises whether this is the
case for adalimumab treatment. This is unknown for
patients with Crohn’s disease. However, in patients
with rheumatoid arthritis, the concomitant use of
methotrexate during adalimumab treatment reduced
the rate of antibody development.14 In our study, the
number of patients was too small to draw conclusions
about the role of concomitant therapy and the forma-
tion of antibodies. A larger study with a longer
follow-up is needed to assess this.
Our results also suggest that patients previously
treated with infliximab with high levels of ATIs have
a lower response rate to adalimumab than patients
with low levels of ATIs. This effect might be
explained hypothetically by the cross reactivity of
ATIs with adalimumab. Yet, infliximab and ada-
limumab are different idiotypes which makes this
type of cross reactivity unlikely. This is also sup-
ported by in vitro observations (G. J. Wolbink,
unpublished data).
The immunogenicity of a biological is determined
by the immune response of an individual patient. High
levels of ATIs that negatively influenced adalimumab
treatment outcome in our study would then be an epi-
phenomenon reflecting the individual immune reac-
tion. Furthermore, rheumatoid arthritis patients with
ATIs have increased ATAs levels (G. J. Wolbink,
unpublished data). Previous clinical observations sug-
gest that a loss of response to infliximab treatment
may affect response to subsequent treatment with ada-
limumab. The GAIN trial also found that adalimumab
was more effective than a placebo in patients with inf-
liximab refractory disease. ATIs did not seem to play a
role, but the relationship with ATIs levels was not
reported in this study.13 In addition, the CHARM study
found that patients naı¨ve to infliximab had a slightly
better response to adalimumab than those who had
previously been treated with infliximab, but this dif-
ference was not statistically significant.12 This suggests
that patients who lose response to an anti-TNF anti-
body never regain full response even when treated
with a different anti-TNF antibody. Predisposition to
antibody formation may be a factor underlying this
phenomenon.
The main limitations of this study are a retrospective
study design and the small number of patients
included. We also did not use an objective measure
such as the Crohn’s Disease Activity Index to assess
clinical response in luminal disease. Nevertheless,
clinical response was assessed by experienced physi-
cians using unequivocal criteria for nonresponse thus
making these findings reliable. As this is a retrospec-
tive study, ATAs were measured at different time
points for each of the patients. However, the minimum
adalimumab treatment duration of 60 days allowed
sufficient time to assess the presence of antibodies.
Furthermore, serum trough adalimumab levels were
not measured. However, it has been shown previously
that the presence of ATAs is associated with low serum
trough adalimumab levels.14 The reduced adalimumab
concentration is probably because of increased clear-
ance of adalimumab via the formation of immune
complexes between ATAs and adalimumab. Thus our
results give a clear indication that ATAs affect ada-
limumab treatment outcome.
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On the basis of our results, we can conclude that
immunogenicity negatively influences response to
adalimumab treatment in Crohn’s disease patients
because of the development of ATAs. This means that
a group of patients will not respond or eventually
lose response to adalimumab treatment because of
the formation of antibodies. Future larger prospective
studies will have to provide more insights into this
group of patients and on what the best treatment
strategy is.
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